Nuveen’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $95M | Sell |
315,630
-6,602
| -2% | -$1.99M | 0.02% | 437 |
|
|
2026
Q1 | $107M | Sell |
322,232
-243,557
| -43% | -$82.9M | 0.03% | 383 |
|
|
2025
Q4 | $225M | Sell |
565,789
-22,032
| -4% | -$9.75M | 0.06% | 244 |
|
|
2025
Q3 | $268M | Sell |
587,821
-187,148
| -24% | -$76.2M | 0.07% | 224 |
|
|
2025
Q2 | $253M | Sell |
774,969
-108,405
| -12% | -$30M | 0.07% | 223 |
|
|
2025
Q1 | $149M | Buy |
883,374
+434,493
| +97% | +$112M | 0.05% | 316 |
|
|
2024
Q4 | $106M | Buy |
448,881
+7,789
| +2% | +$2.05M | 0.03% | 393 |
|
|
2024
Q3 | $121M | Sell |
441,092
-147,377
| -25% | -$38.4M | 0.03% | 377 |
|
|
2024
Q2 | $143M | Buy |
588,469
+76,491
| +15% | +$12.1M | 0.04% | 323 |
|
|
2024
Q1 | $76.5M | Sell |
511,978
-31,433
| -6% | -$5.24M | 0.02% | 491 |
|
|
2023
Q4 | $104M | Sell |
543,411
-3,047
| -0.6% | -$519K | 0.03% | 388 |
|
|
2023
Q3 | $96.8M | Sell |
546,458
-6,221
| -1% | -$1.19M | 0.03% | 379 |
|
|
2023
Q2 | $105M | Sell |
552,679
-56,427
| -9% | -$11.2M | 0.04% | 373 |
|
|
2023
Q1 | $122M | Sell |
609,106
-9,538
| -2% | -$2M | 0.05% | 329 |
|
|
2022
Q4 | $147M | Sell |
618,644
-15,974,624
| -96% | -$3.41B | 0.06% | 295 |
|
|
2022
Q3 | $3.32B | Buy |
16,593,268
+16,296,223
| +5,486% | +$3.11B | 1.35% | 7 |
|
|
2022
Q2 | $43.3M | Sell |
297,045
-64,990
| -18% | -$9.22M | 0.02% | 608 |
|
|
2022
Q1 | $58.8M | Sell |
362,035
-228,509
| -39% | -$34.8M | 0.02% | 572 |
|
|
2021
Q4 | $100M | Sell |
590,544
-176,488
| -23% | -$32.8M | 0.03% | 442 |
|
|
2021
Q3 | $145M | Buy |
767,032
+114,024
| +17% | +$21.4M | 0.04% | 343 |
|
|
2021
Q2 | $111M | Buy |
653,008
+57,008
| +10% | +$8.35M | 0.03% | 444 |
|
|
2021
Q1 | $84.1M | Sell |
596,000
-2,700
| -0.5% | -$406K | 0.03% | 512 |
|
|
2020
Q4 | $77.8M | Buy |
598,700
+171,329
| +40% | +$22.9M | 0.03% | 513 |
|
|
2020
Q3 | $62.2M | Sell |
427,371
-26,197
| -6% | -$3.72M | 0.02% | 503 |
|
|
2020
Q2 | $67.2M | Sell |
453,568
-61,300
| -12% | -$8.26M | 0.03% | 476 |
|
|
2020
Q1 | $56M | Buy |
514,868
+111,311
| +28% | +$12.8M | 0.03% | 460 |
|
|
2019
Q4 | $46.5M | Sell |
403,557
-12,657
| -3% | -$1.26M | 0.02% | 707 |
|
|
2019
Q3 | $33.5M | Buy |
416,214
+25,552
| +7% | +$2.02M | 0.01% | 864 |
|
|
2019
Q2 | $28.3M | Buy |
+390,662
| New | +$30M | 0.01% | 963 |
|
|
2015
Q3 | – | Sell |
-53,550
| Closed | -$6.42M | – | 1558 |
|
|
2015
Q2 | $6.42M | Buy |
+53,550
| New | +$6.4M | 0.03% | 472 |
|
|
2015
Q1 | – | Sell |
-109,216
| Closed | -$10.6M | – | 1588 |
|
|
2014
Q4 | $10.6M | Sell |
109,216
-94,984
| -47% | -$8.8M | 0.06% | 374 |
|
|
2014
Q3 | $15.9M | Buy |
204,200
+28,348
| +16% | +$1.83M | 0.1% | 281 |
|
|
2014
Q2 | $11.1M | Buy |
175,852
+4,073
| +2% | +$242K | 0.07% | 352 |
|
|
2014
Q1 | $11.5M | Buy |
171,779
+121,236
| +240% | +$9.39M | 0.07% | 329 |
|
|
2013
Q4 | $3.25M | Sell |
50,543
-4,368
| -8% | -$261K | 0.02% | 612 |
|
|
2013
Q3 | $3.52M | Buy |
+54,911
| New | +$2.74M | 0.02% | 601 |
|
Other funds holding ALNY
Nuveen's ALNY Position: Q2 2026 in Review
Nuveen reduced its Alnylam Pharmaceuticals (ALNY) stake by 2% in Q2 2026, selling an estimated $1.99M and leaving 315,630 shares worth $95M. The position accounts for 0.02% of the portfolio, ranked #437.
Nuveen first reported a position in ALNY in Q3 2013 and has held it in 36 quarters since. The position peaked at $3.32B in Q3 2022. 787 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Nuveen held 315,630 shares of Alnylam Pharmaceuticals worth $95M as of Q2 2026.
- Nuveen sold 6,602 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
- Alnylam Pharmaceuticals made up 0.02% of Nuveen's portfolio in Q2 2026, its #437 holding.
- Nuveen first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 36 quarters since.
- Nuveen's Alnylam Pharmaceuticals position peaked at $3.32B in Q3 2022.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.